| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Mortality Reduction After Oral Azithromycin: Mortality Study
| Condition: |
Childhood Mortality |
| Interventions: |
Drug: Azithromycin; Drug: Placebo |
| Outcome Measures: |
All-cause Mortality Rate in children aged 1-60 months; Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy; Cost-effectiveness of mass Azithromycin administration, per averted childhood death; All-cause and cause-specific health clinic visits in 1-60 month-old children |
|
| 2 |
Recruiting
|
Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
| Condition: |
Ureaplasma Infections |
| Interventions: |
Drug: Azithromycin; Drug: Placebo (for Azithromycin) |
| Outcome Measures: |
Survival with microbiological eradication of Ureaplasma; Physiologic defined bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age; Death or Neurodevelopmental impairment; Pulmonary impairment; Death; Duration of positive pressure support; Duration of oxygen supplementation; Air leaks; Received postnatal steroids; Received Non-Study antibiotics; Pharmacokinetics (PK)/Pharmacodynamics (PD) modelling of time course of Azithromycin plasma concentrations |
|
| 3 |
Not yet recruiting
|
Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
| Conditions: |
Malaria, Falciparum; Chloroquine; Azithromycin; Immunization |
| Interventions: |
Drug: Azithromycin capsules; Drug: Placebo; Biological: Immunization with falciparum; Drug: Atovaquone/Proguanil; Biological: Challenge with falciparum |
| Outcome Measures: |
Volunteers falciparum positive by thick smear; Duration of pre-patent period by thick smear; Kinetics of parasitemia by PCR; Adverse events; Immune responses |
|
| 4 |
Not yet recruiting
|
Mortality Reduction After Oral Azithromycin: Morbidity Study
| Condition: |
Childhood Mortality |
| Interventions: |
Drug: Azithromycin; Drug: Placebo |
| Outcome Measures: |
Presence of malaria parasites on thick blood smear in children 1-60 months; Fraction of isolates of pneumococcus exhibiting macrolide resistance by nasopharyngeal swabs in children 1-60 months; Fraction of isolates of Staphylococcus aureus exhibiting macrolide resistance by nasal swabs in children 1-60 months; Fraction of isolates of Streptococcus pyogenes exhibiting macrolide resistance by oropharyngeal swabs in children 1-60 months; Evidence of E. coli macrolide resistance in stool specimens in children 1-60 months; Fraction of conjunctival swabs yielding ocular chlamydia in children 1-60 months; Height over time in children aged 1-60 months; Presence of malaria gametocytes, and density of malaria parasites and gametocytes, in children 1-60 months; Rates of malaria parasitemia among children 1-59.9 months.; Hemoglobin concentration and presence of anemia (hemoglobin <11 g/dL) in children 1-60 months; Nasopharyngeal pneumococcal macrolide resistance in individuals 7-12 years; Nasopharyngeal pneumococcal macrolide resistance in children aged 1-60 months seen in local health clinics for a respiratory complaint; Rates of acute respiratory illness among children 1-59.9 months.; Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.; Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.; Presence of the trachoma grades "follicular trachoma" (TF) and "intense inflammatory trachoma" (TI), as defined by the WHO simplified grading system, in children 1-60 months; Trachoma infection and antibody status in children (1-60 months); Rates of diarrhea among children 1-59.9 months.; Carriage rates and proportions E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months; Carriage rates and proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.; Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months; Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months; Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months; Nasopharyngeal methicillin-resistant Staphylococcus aureus in children 1-60 months; Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.; Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.; Nasopharyngeal pneumococcal resistance to penicillin and clindamycin in children 1-60 months; Nasopharyngeal pneumococcal macrolide resistance determinants (ermB and mefA), serotype, and multilocus sequence type in children 1-60 months; Oropharyngeal Streptococcus pyogenes macrolide resistance to penicillin and clindamycin in children 1-60 months; Oropharyngeal Streptococcus pyogenes macrolide resistance determinants (mefA, ermB, ermTR) in children 1-60 months; Microbial diversity in the conjunctival, nasopharyngeal, nasal, oropharyngeal, and intestinal microbiomes of children aged 1-60 months; Serology for exposure to exotic pathogens cross sectional sample of children aged 1-60 months; Knee-heel length and head circumference over time in children aged 1-60 months; Commensal and diarrheagenic E. coli carriage in stool of children aged 1-60 months |
|
| 5 |
Recruiting
|
Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children
| Condition: |
Asthma |
| Interventions: |
Drug: Azithromycin; Drug: Suspension Placebo |
| Outcome Measures: |
To determine if treatment of pre-school children with a history of wheeze who present to an Emergency department (ED) with an acute wheezing episode with Azithromycin for 5 days will resolve their symptoms more quickly; Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will cause these children to use less rescue beta2 agonists than those treated with placebo; Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will allow these children to remain free of subsequent wheezy episodes longer than those treated with placebo. |
|
| 6 |
Not yet recruiting
|
Belgian Trial With Azithromycin During Acute COPD Exacerbations
| Condition: |
Chronic Obstructive Pulmonary Disease |
| Intervention: |
Drug: Azithromycin |
| Outcome Measures: |
Time to treatment failure; Number of treatment failures; Time to new exacerbation; Number of new exacerbations; Rate of exacerbations; Days of hospitalisation; Days of intensive care; Symptom and quality of life scores; Pre- and post-bronchodilator FEV1; Total dose of systemic steroids; Total days of antibiotic use; Number of home physician contacts; Average cost of hospitalization |
|
| 7 |
Not yet recruiting
|
Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
| Conditions: |
Ocular Inflammation; Infection Associated Blepharitis; Keratitis; Conjunctivitis, Bacterial |
| Interventions: |
Drug: Azithromycin 1.5%/Loteprednol 0,5% + placebo; Drug: Azithromycin 1.5% + Loteprednol 0,5% (separately) |
| Outcome Measures: |
Clinical cure; irradication of pathogens |
|
| 8 |
Recruiting
|
Azithromycin for Children Hospitalized With Asthma
| Condition: |
Asthma |
| Interventions: |
Drug: Azithromycin; Drug: Placebo |
| Outcome Measures: |
Length of Stay; Readmission rate; School missed; Work missed; Emergency room visits; Physician office visits; Recurrence of asthma symptoms; Steriod courses |
|
| 9 |
Recruiting
|
Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea
| Conditions: |
Diarrhea; Fever; Vomiting; Abdominal Pain |
| Interventions: |
Drug: Azithromycin; Drug: Placebo |
| Outcome Measures: |
Duration of diarrhea in days; number of stools/day |
|
| 10 |
Recruiting
|
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
| Condition: |
Trachoma |
| Intervention: |
Other: Surveillance and treatment with Azithromycin of newcomer and traveler families |
| Outcome Measures: |
The proportion of communities with C. trachomatis infection prevalence of 1% or below; The proportion of communities with clinical trachoma prevalence of 5% or below; The trajectory of change in prevalence of infection with C. trachomatis and clinical trachoma; The community prevalence of new infections of C. trachomatis and clinical trachoma identified; The presence of active trachoma in children; The presence of trachomatous scarring in women |
|
| 11 |
Recruiting
|
Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation
| Condition: |
Disorder Related to Lung Transplantation |
| Interventions: |
Drug: Azithromycin; Drug: Ora-Plus |
| Outcome Measures: |
Mean forced expiratory volume at one second (FEV1, %pred); Length of intubation; Length of Intensive Care Unit (ICU) stay; Length of hospital stay; Partial Pressure of Oxygen in Arterial Blood over fraction of inspired oxygen fraction - ratio (PaO2/FiO2); Primary graft dysfunction (PGD) prevalence and score; 6-minute walking distance; Acute rejection (grade A; grade B) prevalence/severity; Broncho-alveolar lavage neutrophilia and cytokine/protein profile; Airway colonization; Plasma C-reactive protein levels; Mortality; Ventilator-free days |
|
| 12 |
Recruiting
|
Drug Interaction Study of Azithromycin and Theophylline
| Conditions: |
Chronic Obstructive Pulmonary Disease; Asthma |
| Interventions: |
Drug: Theophylline with Azithromycin; Drug: Theophylline alone |
| Outcome Measure: |
steady-state plasma concentration of theophylline |
|
| 13 |
Unknown †
|
Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
| Condition: |
Cutaneous Leishmaniasis |
| Interventions: |
Drug: N-metil glucamine; Drug: Azithromycin |
| Outcome Measures: |
Proportion of clinically cured patients; Proportion of patients with failure; Occurrence of mucosal lesions after treatment; Proportion of patients presenting new lesions; Proportion of adverse events on each treatment group |
|
| 14 |
Recruiting
|
PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
| Conditions: |
Pharyngitis; Tonsillitis |
| Intervention: |
Drug: Azithromycin |
| Outcome Measure: |
Best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination |
|
| 15 |
Recruiting
|
Azithromycin Against pLacebo in Exacerbations of Asthma
| Condition: |
Asthma |
| Interventions: |
Drug: Zithromax; Drug: Placebo |
| Outcome Measures: |
Diary card summary symptom score; Quality of life; Time to 50% reduction in symptom score; Pulmonary Function tests |
|
| 16 |
Recruiting
|
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
| Condition: |
Crohn's Disease |
| Interventions: |
Drug: Azithromycin + Metronidazole; Drug: Metronidazole |
| Outcome Measures: |
Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle); Normalization of CRP ( CRP ≤0.5 mg/dL).; Fecal calprotectin at 8 weeks . |
|
| 17 |
Recruiting
|
Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children
| Condition: |
Sinusitis |
| Interventions: |
Drug: placebo; Drug: Azithromycin |
| Outcome Measure: |
frequence of acute sinusitis during 12 mouths of study period |
|
| 18 |
Unknown †
|
The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease
| Conditions: |
Cat-scratch Disease; Bartonella Infections |
| Interventions: |
Drug: prednison and Azithromycin; Drug: prednison, Azithromycin; Drug: prednison, Azenil |
| Outcome Measure: |
Severity score of lymphadenitis using a lymphadenitis Score (LS). |
|
| 19 |
Recruiting
|
Prevention of Bacterial Infections in Newborn
| Condition: |
Neonatal Infection |
| Intervention: |
Drug: Azithromycin and Placebo |
| Outcome Measures: |
the prevalence of nasopharyngeal carriage of the newborn of any of the following bacteria: 1) Group B Streptococci (GBS) , 2) S.pneumoniae and 3) S.aureus; Vaginal bacterial Group B Streptococci(GBS), S.pneumoniae and S.aureus) carriage at day six post-delivery. Vaginal bacterial (GBS, S.pneumoniae and S.aureus) carriage at day 8-10 post-delivery |
|
| 20 |
Unknown †
|
the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
| Condition: |
Acne |
| Interventions: |
Drug: Doxycycline; Drug: Azithromycin |
| Outcome Measures: |
change in acne lesions; global response rates, patient's own assessment, side effects and compliance |
|
